Results 181 to 190 of about 275,929 (307)

Large‐scale bidirectional arrayed genetic screens identify OXR1 and EMC4 as modifiers of αSynuclein aggregation

FEBS Open Bio, EarlyView.
Activation of the mitochondrial protein OXR1 increases pSyn129 αSynuclein aggregation by lowering ATP levels and altering mitochondrial membrane potential, particularly in response to MSA‐derived fibrils. In contrast, ablation of the ER protein EMC4 enhances autophagic flux and lysosomal clearance, broadly reducing α‐synuclein aggregates.
Sandesh Neupane, Lea Nikolić, Lorenzo Maraio, Thomas Goiran, Nathan Karpilovsky, Stefano Sellitto, Vangelis Bouris, Jiang‐An Yin, Ronald Melki, Edward A Fon, Adriano Aguzzi, Elena De Cecco   +11 more
wiley   +1 more source

hAb-Convergent: an antibody rearrangement analysis system for therapeutic antibody engineering based on convergent evolution. [PDF]

Nucleic Acids Res
Wang J, Ge X, Sun Q, Chen M, Qin S, Liu D, Deng T, Ma J, Hu S, Jin R, Tong Z, Wu L.   +11 more
europepmc   +1 more source

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein. [PDF]

MAbs, 2021
Suzuki T, Hashii N, Tada M, Ishii-Watabe A.   +3 more
europepmc   +1 more source

Suppression of lung adenocarcinoma migration through organelle alkalization by human lactoferrin – albumin fusion

FEBS Open Bio, EarlyView.
This paper reveals how human lactoferrin–albumin fusion (hLF‐HSA) potently suppresses lung adenocarcinoma cell migration. hLF‐HSA upregulates NHE7, leading to Golgi alkalization, disruption of the Golgi secretome, downregulation of MMP1, and reversal of EMT. These findings suggest a novel Golgi‐targeting strategy to suppress cancer cell migration.
Hana Nopia, Masahiro Kimura, Daisuke Kurimoto, Atsushi Sato   +3 more
wiley   +1 more source

An Engineered Mouse Model That Generates a Diverse Repertoire of Endogenous, High-Affinity Common Light Chain Antibodies

Bispecific antibodies have gained increasing popularity as therapeutics as they enable novel activities that cannot be achieved with monospecific antibodies.
Yinghui Rong, Patrick Koenig, Lance Larrabee, Manali S. Sawant, Germaine Fuh, I-Ling Chen   +5 more
core   +1 more source

Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens. [PDF]

Clin Exp Med
Soleimani Samarkhazan H, Noormohamadi H, Shafiei FS, Taghinejad Z, Maleknia M, Raoufi A, Nouri S, Mohammadi MH.   +7 more
europepmc   +1 more source

Blood‐based proteomic profiling reveals context‐dependent changes in BCL2‐associated signaling during taxane therapy in breast cancer patients

FEBS Open Bio, EarlyView.
Chemotherapy side effects significantly impact cancer survivors' quality of life. Using protein levels in blood samples from breast cancer patients before and after 12 weeks of taxane treatment, we detected treatment‐dependent changes in calcium signaling and aging pathways associated with cancer recurrence.
Saira Munshani, Eiman Y. Ibrahim, Rozalyn L. Rodwin, Leah M. Ferrucci, Kim Blenman, Maryam Lustberg, Barbara E. Ehrlich   +6 more
wiley   +1 more source

Structure-guided bispecific antibody engineering confers broad protection against KP.3.1.1 and sarbecoviruses. [PDF]

iScience
Ma Y, Liu Q, Rehati P, Zhang Z, Wang Y, Liu Z, Chen J, Bai X, Hao A, Wang Y, Wen Y, Chen Z, Lu L, Zhao J, Wu F, Sun L, Huang J.   +16 more
europepmc   +1 more source

Long‐term hippocampal alterations and cognitive impairment in a murine model of surgical sepsis

FEBS Open Bio, EarlyView.
Using a mouse model of surgical sepsis, we tested long‐term memory and analyzed the transcriptome of single cells isolated from the hippocampus. Survivor mice showed worse memory, loss of certain brain cell subpopulations, and abnormal immune cell activity—suggesting that post‐sepsis brain alterations may be linked to cognitive deficits.
Dong Seong Cho, Rebecca Schmitt, Aneesha Dasgupta, Alexandra Ducharme, Jason Doles   +4 more
wiley   +1 more source

Antibody numbering schemes: advances, comparisons and tools for antibody engineering. [PDF]

Protein Eng Des Sel
Zhu Z, Ashrafian H, Tabrizi NM, Matas E, Girard L, Ma H, Nice EC.   +6 more
europepmc   +1 more source